1 2		association between the <i>Plasmodium vivax crt-o</i> MS334 or In9 <i>pvcrt</i> norphisms and chloroquine failure in a clinical cohort from Malaysia
۷	polyli	orphisms and emotoquine failure in a emilear conort nom malaysia
3		
4	Angela	Rumaseb ¹ , Roberto R. Moraes Barros ² , Juliana M. Sá ² , Jonathan J. Juliano ³ , Timothy
5	William	^{4,5} , Kamil A. Braima ¹ , Bridget E. Barber ^{1,6} , Nicholas M Anstey ^{1,5} , Ric N. Price ^{1,7,8} , Matthew
6	J. Grigg	g ^{1,5} , Sarah Auburn ^{17,8*} , Jutta Marfurt ^{1,9*}
7		
8	1.	Global and Tropical Health Division, Menzies School of Health Research and Charles
9		Darwin University, Darwin, Northern Territory, Australia
10	2.	Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious
11		Diseases, National Institutes of Health, Bethesda, MD 20892, USA
12	3.	Division of Infectious Diseases, School of Medicine, University of North Carolina at
13		Chapel Hill, Chapel Hill, NC 27599, USA
14	4.	Clinical Research Centre, Queen Elizabeth Hospital, Sabah, Malaysia
15	5.	Infectious Diseases Society Sabah-Menzies School of Health Research Clinical Research
16		Unit, Kota Kinabalu, Sabah, Malaysia
17	6.	QIMR Berghofer Medical Research Institute, Brisbane, Australia
18	7.	Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,
19		University of Oxford, Oxford, United Kingdom
20	8.	Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok,
21		Thailand
22	9.	College of Medicine and Public Health, Flinders University, Darwin, Northern Territory,
23		Australia
24		
25	*These	authors contributed equally
26	Corresp	pondence to Associate Professor Sarah Auburn, <u>Sarah.Auburn@menzies.edu.au</u>
27		
28	Keywo	ords
29	Plasmod	lium, vivax, malaria, chloroquine, antimalarial, drug resistance, molecular marker, pvcrt-o,
30	Monteyra	. Mas preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 Abstract

- 32 Increasing reports of resistance to a frontline malaria blood-stage treatment, chloroquine (CQ),
- raise concerns for the elimination of *Plasmodium vivax*. The absence of an effective molecular
- 34 marker of CQ resistance in *P. vivax* greatly constrains surveillance of this emerging threat. A
- 35 recent genetic cross between CQ sensitive (CQS) and CQ resistant (CQR) NIH-1993 strains of
- 36 *P. vivax* linked a moderate CQR phenotype with two candidate markers in *P. vivax* CQ resistance
- 37 transporter gene (*pvcrt-o*): MS334 and In9*pvcrt*. Longer TGAAGH motifs at MS334 were
- associated with CQ resistance, as were shorter motifs at the In9pvert locus. In this study, high-
- 39 grade CQR clinical isolates of *P. vivax* from Malaysia were used to investigate the association
- 40 between the MS334 and In9*pvcrt* variants and treatment efficacy. Amongst a total of 49
- 41 independent monoclonal *P. vivax* isolates assessed, high-quality MS334 and In9*pvcrt* sequences
- 42 could be derived from 30 (61%) and 23 (47%), respectively. Five MS334 and six In9*pvcrt* alleles
- 43 were observed, with allele frequencies ranging from 2 to 76% and 3 to 71%, respectively. None
- 44 of the clinical isolates had the same variant as the NIH-1993 CQR strain, and none were
- 45 associated with CQ treatment failure (all p > 0.05). Our findings suggest that the *pvcrt-o* MS334
- 46 and In9*pvcrt* markers cannot be used universally as markers of CQ treatment efficacy in an area
- 47 of high-grade CQ resistance. Further studies applying hypothesis-free genome-wide approaches
- 48 are warranted to identify more effective CQR markers for *P. vivax*.

Introduction 49

- 50 Plasmodium vivax malaria remains an important public health burden affecting the poorest and
- most vulnerable communities of more than 49 endemic countries (1, 2). Chloroquine (CQ) is still 51
- 52 the most widely used antimalarial drug to treat P. vivax but increasing reports of chloroquine
- 53 resistance highlight the importance of surveillance of its clinical efficacy (3). Although
- surveillance of clinical efficacy is the gold standard for the detection of CQ resistance, challenges 54
- 55 in discriminating infections deriving from blood stage failures (recrudescence), new mosquito
- inoculations (reinfections) and reactivation of dormant liver stages (relapses) confounds robust 56
- 57 clinical estimates of CQ resistance (4). Molecular surveillance presents a more accurate and cost-
- 58 effective strategy to identify drug resistant infections (5). However, the genetic basis of CQ
- 59 resistance in P. vivax remains unclear.

Several studies have investigated Single Nucleotide Polymorphisms (SNPs) in orthologues of 60

61 genes involved in CQ resistance in *P. falciparum*, namely *pvcrt-o* and *pvmdr1*, but none of these

62 markers have been confirmed to be associated with clinical outcomes following CQ treatment of

P. vivax (6-9). Other studies have reported an association between pvert-o expression levels and P. 63

vivax CQ resistance (10-13). However, no evidence of association was observed between pvert-o 64

- 65 expression and ex vivo drug susceptibility phenotypes using clinical isolates from Papua Indonesia
- (14), an area where high rates of clinical failure have been documented following CQ treatment 66
- (15). 67
- More recently, a genetic cross between *P. vivax* subpopulations differing in susceptibility to CQ 68
- in non-human primates identified two new, non-coding *pvcrt-o* markers associated with *in vivo* CQ 69
- 70 sensitivity: a repeat length polymorphism (MS334) and an intron 9 polymorphism (In9pvert) (12).
- 71 The MS334 locus is located approximately 0.6 Kb upstream of the start codon of *pvcrt-o*; CQ
- 72 sensitive (CQS) progeny contained 10 TGAAGH motifs, whilst CQ resistant (CQR) progeny
- 73 carried a longer fragment of 15 TGAAGH motifs. At the In9pvcrt locus, 17 TGAAGH motifs
- were present in CQS progeny, whereas a shorter fragment comprising 14 TGAAGH motifs were 74
- 75 present in CQR progeny.
- 76 The aim of the current study was to correlate the *pvcrt-o* MS334 and In9*pvcrt* markers with clinical 77 outcomes following CQ treatment in patients enrolled into a prospective clinical trial conducted
- in Sabah, Malaysia (16). In this trial more than 60% of patients had recurrent parasitaemia within
- 78
- 79 28 days of treatment, indicative of high-grade CQ resistance (3, 4, 16).

80 Materials and Methods

81 Sample Collection and Selection

Clinical isolates of *P. vivax* were collected from a comparative efficacy study of patients with 82 uncomplicated vivax malaria conducted in Sabah, Malaysia, between 2012 and 2014 (Clinical 83 Trials Registration number NCT01708876) (16). Briefly, consenting patients aged ≥ 1 year and 84 weighing >10kg, presenting with acute, uncomplicated vivax malaria to the study hospitals in 85 Kudat, Kota Marudu and Pitas were recruited into the prospective study. Patients were randomly 86 87 assigned to either CQ (median total dose of 27.7 mg/kg [range, 25.0-33.0]) or artesunatemefloquine (AS-MQ) (median 11.0 mg/kg [range, 9.8–12.0] AS and 27.6 mg/kg [range, 24.6– 88 30.0] MQ), and followed for 42 days. Administration of primaguine for radical cure was delayed 89 until 28 days of follow up. All treatment doses of chloroquine were supervised. The primary 90 91 outcome was the cumulative risk of P. vivax parasitaemia by day 28. Blood samples were 92 collected at enrolment and on the day of recurrence for molecular analyses. Monoclonal P. vivax 93 isolates collected at enrolment into the CQ treatment were selected for further molecular analysis in the *pvcrt-o* study. Isolates were categorized as CQS if the patient exhibited adequate parasite 94 clearance and no recurrent parasitaemia within 42 days. If patients failed to clear peripheral 95 96 parasitaemia on blood smear or presented with recurrent P. vivax parasitaemia within 42 days after CQ treatment in the presence of a minimum effective plasma concentration of chloroquine 97 98 and desethylchloroquine (CQ+DCQ) of ≥ 15 mL at Day 7 (corresponding to a whole blood concentration of 100ng/mL) (17), they were defined as CQR (16-18). All patient samples and 99 corresponding clinical data were assigned unique study code identifiers (not identifiable to 100 101 anyone outside the research group) to protect the identity of the subjects.

102

103 DNA Extraction, Speciation, and Genotyping

104 DNA was extracted from 200 µL whole blood using the QIAamp DNA Blood extraction kit

105 according to the manufacturer's procedures (Qiagen, Germany). *Plasmodium spp.* was confirmed

using the multiplex PCR method described by Padley et al. (19). *P. vivax* genotyping data was

107 derived from published data stored in the open access vivaxGEN-MS platform

108 (<u>https://vivaxgen.menzies.edu.au</u>) using batch code MYPV-MG and applying the default

109 parameters for genotype calling (20). Briefly, genotyping was performed using capillary

110 electrophoresis at nine short tandem repeat (STR) markers to determine the multiplicity of

111 infection (MOI) as previously described (21).

113 *pvcrt-o* Gene Fragment Amplification and Sanger Sequencing

- 114 The primer sequences and PCR cycling conditions are summarised in **Table 1**. The PCR
- 115 products were run on 2% agarose gel, stained with SYBRTM Safe DNA Gel Stain (Invitrogen,
- 116 USA) and visualized using the Molecular Imager Gel Doc XR system (Bio-Rad, USA). PCR
- amplification of In9*pvcrt* yielded multiple bands and henceforth gel extraction was required prior
- to sequencing, as conducted on previous experiments. Amplicons were sent to Macrogen Inc
- 119 (Seoul, South Korea), where PCR product purification by gel extraction was conducted prior to
- 120 sequencing using the dideoxy termination method and the respective PCR primers.
- 121

122 Sequence Analysis

- 123 Trimming low-quality ends of the sequences were performed using Mega-X software (Version
- 124 10.2.5). Post-trimming, manual assembly of contigs and comparison with the gene regions of the
- 125 CQS reference Sal-1 strain were performed using BioEdit software (Version 7.2.5). Alignments
- 126 were undertaken with the bioinformatician blinded to the CQ treatment outcomes of the
- 127 patients. To ensure consistency in assemblies between the genetic cross study (12) and the
- 128 current study, the NIH-1993-S and NIH-1993-R sequences described in the former study were
- 129 analysed alongside the Malaysian assemblies.
- 130

131 Statistical Analysis

All statistical tests were conducted using in-built functions of R (Version 1.2.5042). Proportions were assessed using the Chi-squared test with Yates' correction and Wilcoxon test was used for non-parametric comparisons. A significance threshold of p<0.05 was used for all statistical comparisons.

136

137 Ethics

All samples were collected with written informed consent from patient or legal guardian for
individuals less than 18 years of age. Ethical approval for the patient sampling and parasite
molecular analysis was provided by the Human Research Ethics Committee of the Northern
Territory Department of Health and Families (HREC-2010-1431, HREC-2012-1815 and HREC-

- 142 2010-1396), the National Medical Research Ethics Committee, Ministry of Health, Malaysia
- **143** (NMMR-10-754-6684, NMRR-12-511-12579).
- 144

145 **Results**

146 Summary of patient samples and sequencing data

- 147 The filtering process for all samples used in the study is presented in Figure 1. Amongst 49
- 148 clinical samples collected at baseline from patients treated with CQ, high-quality sequences could
- 149 be derived from independent monoclonal *P. vivax* infections for MS334 in 30 (61%) isolates and
- 150 In9*pvcrt* in 23 (47%) isolates. An additional 9 high-quality sequences at MS334 and 3 at In9*pvcrt*
- 151 were also derived in paired isolates at baseline and day of recurrence. Details of the clinical
- 152 characteristics of the patients and assay results of the isolates are presented in **Supplementary**
- **153** File 1. There were no significant differences in age, gender, and baseline parasitaemia between
- 154 the *pvert-o* study set and all patients treated with CQ in the trial (**Table 2**).
- 155 Sequencing data on the successfully sequenced and aligned MS334 and In9*pvcrt* amplicons are
- deposited in Genbank under accession numbers OP807877 OP807946. The sequencing pass
- rates amongst the baseline and recurrent infections were 91% (41/45) for MS334 and 69%
- **158** (31/45) for In9*pvcrt*.
- 159

160 Summary of MS334 and In9*pvcrt* variants observed in Malaysia

- 161 A summary of the MS334 and In9*pvert* genotype calls is provided in **Table 3**. Five MS334 and six
- 162 In *pvcrt* insertion and deletion (indel) variants were identified amongst the Day 0 and recurrent
- 163 Malaysian isolates, with allele frequencies ranging from 2% (1/41) to 76% (31/41) and 3%
- 164 (1/31) to 71% (22/31), respectively. Representative sequences of the 5 MS334 and 6 In9*pvrt*
- 165 indels observed in Malaysia, as well as the NIH-1993-R and NIH-1993-S strains, aligned against
- the Sal-1 reference strain, are provided in **Supplementary Files 2 and 3**.
- 167 At the MS334 locus, longer TGAAGH motifs were associated with CQR in the NIH-1993-R×S
- strains (12). The NIH-1993-R type (inferred CQR type) MS334 allele comprising the 15
- 169 TGAAGH motifs was not observed in Malaysia, and all variants at this locus exhibited shorter
- 170 motif lengths, ranging from 8-11 motifs. Most clinical isolates also contained motifs shorter than
- **171** the NIH-1993-S (10 motifs) type.

172 At the In9*pvcrt* locus, shorter TGAAGH motifs were associated with CQR in the NIH-1993

- strains (12). The NIH-1993-R type In9*pvcrt* allele comprising 14 TGAAGH motifs was not
- 174 observed in the clinical isolates from Malaysia, but motif lengths ranging from 7-17 were
- 175 observed. Most infections contained 10 TGAAGH motifs (22/31; 71%), which is shorter than
- both the NIH-1993-R (14 motifs) and NIH-1993-S (17 motifs) types. The distribution of the
- 177 different TGAAGH (TGAAGC, TGAAGA, TGAAGT) motif lengths observed in clinical CQS,
- 178 CQR and recurrent isolates are summarised in Figure 2.
- 179

180 Assessment of MS334 and In9*pvcrt* association with CQ treatment outcome

181 There was no statistically significant difference in the proportion of any of the five MS334 or six

- 182 In9*pvcrt* alleles (all *p*>0.05) between CQS and CQR clinical isolates; **Table 3**. Although none of
- the clinical isolates carried the exact motifs of the NIH-1993-R strains at the MS334 and In9*pvcrt*
- 184 loci, the Malaysian MS334 variant types 4 and 5, and In9*pvcrt* variant types 3, 4 and 5 possessed
- 185 fragments of the NIH-1993-R indels (Supplementary Files 2 and 3). However, there was no
- significant difference in the proportion of the combined MS334 variants4 and 5 or combined
- 187 In *pvcrt* variants 3, 4 and 5 between the CQS and CQR isolates as summarised in **Table 4**.
- **188** Further assessment of the MS334 and In9*pvcrt* variants was undertaken in paired isolates at
- 189 baseline and the day of recurrent parasitaemia. Seven of the 9 pairs successfully sequenced at
- 190 MS334 and all 3 pairs sequenced at In9*pvcrt* exhibited the same alleles at both time points (**Table**
- **191 5**). In the two pairs exhibiting allelic differences at MS334 (MV019 and TK026 pairs), the
- 192 changes in variants pre- and post-treatment were not consistent. One pair possessed a longer
- allele at baseline, and the other pair possessed a longer allele at recurrence. Analysis of
- 194 microsatellite-based genotyping data in two paired isolates revealed evidence of polyclonal
- 195 infection at recurrence but not at baseline (**Table 6**).
- 196

197 Discussion

- **198** The involvement of *pvcrt-o* in conferring CQ resistance in *P. vivax* has been investigated in several
- 199 studies over the past two decades but remains contentious (8, 10-14, 22). A recent study using a
- 200 genetic cross between CQS and moderate (surviving paediatric CQ doses) CQR parasite
- subpopulations of the NIH-1993-S×R strain linked *pvcrt-o* transcription to CQ resistance and two
- 202 candidate markers in the gene region (MS334 and In9*pvcrt*)(12). Our study provides the first

203 investigation of the MS334 and In9*pvcrt* variants using samples from a CQ clinical efficacy trial

- 204 (16). Using patient isolates from a clinical trial of CQ efficacy on *P. vivax* undertaken in Sabah,
- 205 Malaysia, a region with high-grade CQR during the sample collection period and at a time of
- residual vivax endemicity, we found that neither MS334 nor In9pvert could predict the clinical
- 207 outcome following CQ treatment.

The genetic cross conducted by Sá and colleagues identified variable TGAAGH motif lengths at 208 209 MS334 and In9pvcrt as markers of in vivo CQ efficacy (in an Aotus host) in CQS and CQR progeny, and that CQR progeny had increased expression of *pvcrt*-o (12). However, it is unclear 210 whether either of these indels has a causative role in determining the response to CO through 211 increased *pvcrt*-o expression or other mechanisms. Interestingly, a study of gene expression 212 213 across lifecycle stages in P. vivax isolates from Cambodia showed that pvert-o has multiple potential protein isoforms due to the retention of intron 9 that predicted an early stop codon 214 215 (23). Another study, conducted on clinical isolates from Thailand and Indonesia, identified an AAG trinucleotide insertion in the *pvcrt-o* exon 1 encoding an extra lysine, associated with 216 reduced CO IC₅₀s, although the insertion was observed predominantly in Thai isolates (76%) 217

- rather than Indonesian isolates (2.2%); the study was potentially confounded by population
- 219 structure effects (7). TGAAGH motifs have been shown to regulate gene expression in
- 220 Arabidopsis, but there is currently no knowledge regarding their role in Plasmodium (24, 25). In
- 221 Malaysia, we observed a wide variety of TGAAGH motif lengths in both MS334 and In9pvcrt
- amongst CQS and CQR isolates, with no evidence of a correlation between motif length and
- clinical outcome following treatment with CQ. For example, the Malaysian CQR isolate TV005
- possessed the shortest TGAAGH motif lengths in both gene regions, while one CQR isolate
- collected at recurrence, MK2079, possessed the longest motif lengths in both gene regions.

226 Although increased *pvcrt-o* expression has been associated with CQ resistance in several studies

- 227 (10-12), this pattern has not been replicated in clinical datasets of populations with high-grade
- 228 CQ resistance. Study of clinical *P. vivax* isolates from Papua, Indonesia, an area of high-grade CQ
- resistance, found no evidence of association between *pvcrt-o* expression and *ex vivo* CQ
- 230 susceptibility (14). Furthermore, although a population genomic study using phenotype-free
- 231 methods to detect selective sweeps identified a weak signal of selection in the vicinity of *pvcrt-o* in
- an Ethiopian population, this signal was not identified in similar studies conducted in either
- 233 Malaysia or Papua, Indonesia, where high grade CQ resistance is present (26-28). It is possible
- that different CQ resistance mechanisms are involved in different *P. vivax* populations.
- Alternatively, the CQ resistance mechanism may not be heritable, in which case studies applying

population genomic approaches to detect sweeps or association methods using pre-treatmentclinical isolates may fail to identify a signal.

238 In the current study, we analysed paired isolates collected at baseline and again on recurrence to explore any changes in the TGAAGH motif lengths after drug exposure. Although the sample 239 size was limited, there was no evidence of an association between MS334 or In9pvcrt motif length 240 and CQ resistance. Six paired isolates had different MS334 motif lengths pre and post treatment, 241 242 however the direction of change (i.e., increase versus decrease in motif length) was inconsistent. Microsatellite-based genotyping data confirmed that the post treatment isolates were the same 243 strains as those present at pre-treatment, except for two pairs, MV019/MV1019 and 244 TK026/TK1026; in these pairs, the isolate at baseline was monoclonal, but the isolates at 245 246 recurrence comprised at least two strains. It's plausible that a polyclonal infection was present at both baseline and recurrence, but a minor CQR strain was only detected at recurrence following 247 248 preferential growth under selective drug pressure. Malaysia is in the pre-elimination stage at the time of the trial, with intense drug pressure resulting in P. vivax population bottlenecking, and 249 thus P. vivax COR strains could be present and circulating in the population as the last remaining 250 251 parasites (26). CQ was the first-line treatment throughout the study period and in view of its very poor efficacy, in 2016 national antimalarial policy was changed to recommend artemisinin 252

253 combination therapies for the treatment of *P. vivax*.

Our study has several limitations. The extensive sequence complexity in the MS334 and In9pvcrt 254 255 regions, and the high diversity of variants observed in the Malaysian population imposed challenges in sequence alignment and variant calling. To overcome these challenges, we confined 256 our study to high quality monoclonal infections and two independent investigators, both blinded 257 258 to the sample's CQ sensitivity status, analysed the molecular assemblies. We were unable to rule 259 out the potential impact of host or other parasitological factors that might impact CQ treatment 260 outcome in the Malaysian study. All patients treated with CQ in our study had observed administration with correct dosage based on body weight and confirmed therapeutic plasma CQ 261 concentrations at day 7 (16). At the time of recurrence, 9 of 20 patients assessed in the original 262 study had plasma CQ + DCQ concentrations in excess of 15 ng/mL (range, 19.7-to 120.5), 263 demonstrating parasite growth in the presence of adequate drug concentrations (16). By 264 265 definition, these parasites were CQR. Furthermore, the risk of recurrence by day 28 exceeded 60%, far higher than that expected under the conditions of a clinical trial (3). Our study was also 266

- 267 limited by small sample size, and despite the near-equal proportions of the two treatment
- 268 outcome groups, there was no trend in our findings.

- 269 In summary, our study found that the MS334 and In9*pvcrt* markers were not effective predictors
- 270 of clinical outcome following CQ treatment of patients with *P. vivax* malaria in Malaysia. Further
- 271 studies exploring the mechanism of *P. vivax* CQ resistance and the identification of molecular
- 272 markers using candidate-free genome-wide approaches are warranted.
- 273

274 Acknowledgements

We thank the participants in this study; the Malaysian clinical and laboratory research staff; the 275 276 Director-General of Health, Malaysia; Kim Piera and Ammar Aziz for conducting the polymerase chain reaction for species diagnosis; and Irene Handayuni for conducting the microsatellite 277 278 genotyping. The study was funded by the National Health and Medical Research Council (NHMRC) Australia Ideas Grant (APP2001083) awarded to SA, program Grant 1037304, project 279 grant 1045156, and a Senior Principal Research Fellowship to NMA (1135820)], Malaysian 280 Ministry of Health (grant BP00500420), and the AusAID Asia-Pacific Malaria Elimination 281 Network (grant 108-07). The work was also supported by the Australian Centre for Research 282 Excellence on Malaria Elimination (ACREME), funded by the National Health and Medical 283 Research Council of Australia (APP1134989). 284

285

286 **References**

Auburn S, Cheng Q, Marfurt J, Price RN. The changing epidemiology of Plasmodium vivax: Insights from conventional and novel surveillance tools. PLoS Med. 2021;18(4):e1003560.
 WHO. World Malaria Report 2021. Organization WH; 2021.

290 3. Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ. Global extent of
291 chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis.
2014;14(10):982-91.

4. Price RN, Auburn S, Marfurt J, Cheng Q. Phenotypic and genotypic characterisation of
drug-resistant Plasmodium vivax. Trends Parasitol. 2012;28(11):522-9.

5. Jacob CG, Thuy-Nhien N, Mayxay M, Maude RJ, Quang HH, Hongvanthong B, et al.
Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination. Elife. 2021;10.

- Brega S, Meslin B, de Monbrison F, Severini C, Gradoni L, Udomsangpetch R, et al.
 Identification of the Plasmodium vivax mdr-like gene (pvmdr1) and analysis of single-nucleotide
 polymorphisms among isolates from different areas of endemicity. J Infect Dis. 2005;191(2):2727.
- 302 7. Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E, Kosaisavee V, et al.
 303 Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular
 304 polymorphisms. PLoS One. 2007;2(10):e1089.
- 305 8. Orjuela-Sanchez P, de Santana Filho FS, Machado-Lima A, Chehuan YF, Costa MR,
 306 Alecrim M, et al. Analysis of single-nucleotide polymorphisms in the crt-o and mdr1 genes of

medRxiv preprint doi: https://doi.org/10.1101/2022.11.30.22282917; this version posted December 1, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

307 Plasmodium vivax among chloroquine-resistant isolates from the Brazilian Amazon region.308 Antimicrob Agents Chemother. 2009;53(8):3561-4.

309 9. Sá JM, Nomura T, Neves J, Baird JK, Wellems TE, del Portillo HA. Plasmodium vivax:
310 allele variants of the mdr1 gene do not associate with chloroquine resistance among isolates from
311 Brazil, Papua, and monkey-adapted strains. Exp Parasitol. 2005;109(4):256-9.

312 10. Fernandez-Becerra C, Pinazo MJ, Gonzalez A, Alonso PL, del Portillo HA, Gascon J.
313 Increased expression levels of the pvcrt-o and pvmdr1 genes in a patient with severe Plasmodium
314 vivax malaria. Malar J. 2009;8:55.

315 11. Melo GC, Monteiro WM, Siqueira AM, Silva SR, Magalhaes BM, Alencar AC, et al.
316 Expression levels of pvcrt-o and pvmdr-1 are associated with chloroquine resistance and severe
317 Plasmodium vivax malaria in patients of the Brazilian Amazon. PLoS One. 2014;9(8):e105922.

318 12. Sa JM, Kaslow SR, Moraes Barros RR, Brazeau NF, Parobek CM, Tao D, et al.
319 Plasmodium vivax chloroquine resistance links to pvcrt transcription in a genetic cross. Nat
320 Commun. 2019;10(1):4300.

321 13. Sa JM, Yamamoto MM, Fernandez-Becerra C, de Azevedo MF, Papakrivos J, Naude B, et
322 al. Expression and function of pvcrt-o, a Plasmodium vivax ortholog of pfcrt, in Plasmodium
323 falciparum and Dictyostelium discoideum. Mol Biochem Parasitol. 2006;150(2):219-28.

14. Pava Z, Handayuni I, Wirjanata G, To S, Trianty L, Noviyanti R, et al. Expression of
Plasmodium vivax crt-o Is Related to Parasite Stage but Not Ex Vivo Chloroquine Susceptibility.
Antimicrob Agents Chemother. 2016;60(1):361-7.

Ratcliff A, Siswantoro H, Kenangalem E, Wuwung M, Brockman A, Edstein MD, et al.
Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine
and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg.
2007;101(4):351-9.

331 16. Grigg MJ, William T, Menon J, Barber BE, Wilkes CS, Rajahram GS, et al. Efficacy of
332 Artesunate-mefloquine for Chloroquine-resistant Plasmodium vivax Malaria in Malaysia: An
333 Open-label, Randomized, Controlled Trial. Clin Infect Dis. 2016;62(11):1403-11.

Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, Suradi, et al. Diagnosis of
resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine
levels. Am J Trop Med Hyg. 1997;56(6):621-6.

337 18. WHO. Methods for surveillance of antimalarial drug efficacy. 2009.

Padley D, Moody AH, Chiodini PL, Saldanha J. Use of a rapid, single-round, multiplex
PCR to detect malarial parasites and identify the species present. Ann Trop Med Parasitol.
2003;97(2):131-7.

20. Trimarsanto H, Benavente ED, Noviyanti R, Utami RA, Trianty L, Pava Z, et al.
VivaxGEN: An open access platform for comparative analysis of short tandem repeat genotyping
data in Plasmodium vivax populations. PLoS Negl Trop Dis. 2017;11(3):e0005465.

Abdullah NR, Barber BE, William T, Norahmad NA, Satsu UR, Muniandy PK, et al.
Plasmodium vivax population structure and transmission dynamics in Sabah Malaysia. PLoS One.
2013;8(12):e82553.

347 22. Silva SR, Almeida ACG, da Silva GAV, Ramasawmy R, Lopes SCP, Siqueira AM, et al.
348 Chloroquine resistance is associated to multi-copy pvcrt-o gene in Plasmodium vivax malaria in
349 the Brazilian Amazon. Malar J. 2018;17(1):267.

350 23. Kim A, Popovici J, Vantaux A, Samreth R, Bin S, Kim S, et al. Characterization of P. vivax
351 blood stage transcriptomes from field isolates reveals similarities among infections and complex
352 gene isoforms. Sci Rep. 2017;7(1):7761.

24. Pertea M, Mount SM, Salzberg SL. A computational survey of candidate exonic splicingenhancer motifs in the model plant Arabidopsis thaliana. BMC Bioinformatics. 2007;8:159.

355 25. Ho LH, Giraud E, Uggalla V, Lister R, Clifton R, Glen A, et al. Identification of regulatory

356 pathways controlling gene expression of stress-responsive mitochondrial proteins in Arabidopsis.

357 Plant Physiol. 2008;147(4):1858-73.

26. Auburn S, Benavente ED, Miotto O, Pearson RD, Amato R, Grigg MJ, et al. Genomic 358 analysis of a pre-elimination Malaysian Plasmodium vivax population reveals selective pressures 359 and changing transmission dynamics. Nat Commun. 2018;9(1):2585. 360


Auburn S, Getachew S, Pearson RD, Amato R, Miotto O, Trimarsanto H, et al. Genomic 361 27. Analysis of Plasmodium vivax in Southern Ethiopia Reveals Selective Pressures in Multiple 362 363 Parasite Mechanisms. J Infect Dis. 2019;220(11):1738-49.

Pearson RD, Amato R, Auburn S, Miotto O, Almagro-Garcia J, Amaratunga C, et al. 364 28.

Genomic analysis of local variation and recent evolution in Plasmodium vivax. Nat Genet. 365

366 2016;48(8):959-64.

368 List of Figures



- **Figure 1. Flowchart outlining patient sample exclusion.** Abbreviations: *Pv*, *Plasmodium vivax;*
- 371 CQ, Chloroquine; PCR, polymerase chain reaction; CQS, chloroquine sensitive; CQR, chloroquine
- 372 resistant; Rec, recurrent infection time point.




Figure 2. Dot-boxplots of TGAAGH motif lengths observed in Malaysian isolates.
Abbreviations: CQS, chloroquine sensitive (day 0 infections); CQR, chloroquine resistant (day 0 infections); Rec, recurrent infection time point.

377 List of Tables

Primer Pair	Primer Sequence (5' – 3')	PCR Cycling Condition
MS334_F	GAAATGTAGATTTAAGTGCA	94°C for 2 min, 40 cycles of (94°C for 30sec, 48°C
MS334_R	TGTCACTTTGTCAAATAACA	for 45sec, 72°C for 45sec), 72°C for 5min
Intron9_F	GGTTGGAATGCCAGATG	94°C for 2 min, 40 cycles of (94°C for 30sec, 55°C
Intron 9_R	TCGCAAATGTTGAAAAAGGA	for 45sec, 72°C for 45sec), 72°C for 5min

Table 1. Primer sequences and PCR cycling conditions. PCR = Polymerase Chain Reaction

		Age* N(%)		Males N(%)	Asexual parasitemia ⁱ		
	<5	5-15	>15	- iviaics 1 v (70)	median (range)		
Baseline [§]	1/49 (2.04)	23/49 (46.94)	25/49 (51.02)	33/49 (67.35)	3131 (240-42,521)		
Study+	0/34 (0)	17/34 (50)	17/34 (50)	20/34 (58.82)	2933 (408-42,521)		
Test	X ² =2.218e-31	$X^2 = 0.003$	$X^2 = 0$	$X^2 = 0.316$	W= 820		
statistic	(<i>p</i> =1)	(<i>p</i> =0.959)	(<i>p</i> =1)	(<i>p</i> =0.574)	(<i>p</i> =0.908)		
(p-value)							

380

Table 2. Demographic data of CQ-assigned participants in clinical trial and *pvcrt-o* study 381

set. Symbols: *Age in years, ⁱParasites/µL, [§] Participants assigned CQ on baseline, ⁺Participants 382

included in the *pvcrt-o* study set. 383

Candidate	Variant	Indel	Positions*	CQS	CQR	X ² §	Rec
Marker	no.	polymorphism(s)			•	(p-value)	
MS334	1	None	NA	1/17	0/13	6.924e-33	0
		Tone	1 111	1/1/	0/10	(<i>p</i> =1)	0
	2	16bp insertion	-52	14/17	10/13	3.346e-32	7
		roop moerdon		1 1/ 1/	10/10	(<i>p</i> =1)	
	3	16bp insertion	-52	1/17	2/13	0.060	1
		16bp deletion	+43	1/1/	2/10	(p=0.806)	1
	4	16bp insertion	-52	1/17	0/13	6.924e-33	0
		16bp insertion ⁱ	+59	1/1/	0/10	(p=1)	0
	5	32bp insertion	-52	0/17	1/13	0.019	2
		16bp insertion ⁱ	+59	0/1/	1/10	(<i>p</i> =0.891)	-
In9 <i>pvcrt</i>	1	None	NA	0/14	0/9	NA	1
	2	41bp deletion	+3121	1/14	0/9	1.584e-31	0
				-,	075	(<i>p</i> =1)	, in the second s
	3	120bp deletion ⁱ	+3135	1/14	1/9	1.259e-32	2
		1205p deletion	0.000	-,	- / -	(<i>p</i> =1)	_
	4	140bp deletion ⁱ	+3135	11/14	7/9	5.980e-31	4
		r tosp defedion		11/11	.,	(<i>p</i> =1)	
	5	220bp deletion ⁱ	+3095	0/14	1/9	0.052	0
		20bp insertion	+3289	~ / - .	- / -	(<i>p</i> =0.820)	
	6	180bp deletion	+3095	1/14	0/9	1.584e-31	0
		r		-,	~ / -	(<i>p</i> =1)	~

384

Table 3. Summary of insertion and deletion variants observed in Malaysia. Abbreviations 385 and symbols: Indels, Insertion and deletion; *Number of base pairs upstream (-) or downstream 386 (+) from the start of *pvcrt-o* in Sal-1 strain (Pv_Sal1_chr01:330,260); ^{\$} Chi-squared test of CQS vs 387 CQR baseline (i.e., not including the recurrent time point) isolates; ⁱ Part of polymorphisms 388 observed in NIH-1993-R mentioned by (12); CQS, chloroquine sensitive; CQR, chloroquine 389 390 resistant; Rec, recurrent infection time point. See Supplementary Files 2 and 3 for sequence 391 details for each variant.

Variant	Coordinate	CQS	CQR	X^2 (<i>p</i> -value)
MS334; 16bp insertion	Pv_Sal1_chr01:330,319	1/17	1/13	4.016e-31 (p=1.000)
In9pvcrt; 120-220bp deletion	Pv_Sal1_chr01:333,355	13/14	9/9	1.584e-31 (p=1.000)

392

Table 4. Summary of NIH-1993-R-type insertion and deletion polymorphisms observed in 393

Malaysia. Abbreviations and symbols: CQS, chloroquine sensitive; CQR, chloroquine resistant. 394

		Insertion	at 330,319*	Deletion at 333,355* (<i>In9pvcrt</i>)		
		(MS	8334)			
Pair	Sample	Day 0	Day Rec	Day 0	Day Rec	
1	MK079	-	\checkmark	-	Х	
2	MV010	Х	-	-	-	
3	MV019	\checkmark	Х	-	\checkmark	
4	MV021	Х	Х	\checkmark	\checkmark	
5	MV033	Х	Х	-	\checkmark	
6	ТК026	Х	\checkmark	\checkmark	-	
7	TV029	Х	Х	-	\checkmark	
8	TV038	Х	Х	\checkmark	-	
9	TV040	Х	Х	\checkmark	\checkmark	
10	TV048	Х	Х	\checkmark	\checkmark	
11	TV051	Х	Х	-	-	

395

Table 5. Summary of NIH-1993-R-type insertion and deletion polymorphisms observed 396

in paired Malaysian isolates. Abbreviations and symbols: * Positions at chromosome 1 of Sal-397


1 reference strain; Rec, recurrent infection time point; (-) not amplified; (\checkmark) insertion/deletion is 398

present; (X) insertion/deletion is not present. Infections with day 0 versus recurrence 399

differences are highlighted in bold. 400

													Indel Mutation Similarities	
Pair	Sample	MS12	pv3.27	msp1f3	MS10	MS5	MS1	MS8	MS16	MS20	MLG*	MS334	In9pvcrt	
1	MK079	209	280	258	195	194	237	281	385	201	1			
1	MK2079	209	280	258	195	194	237	281	385	201	1	-	-	
2	MV010	206	280	261	180	182	237	263	352	201	2			
2	MV1010	206	280	261	180	182	237	263	352	201	2	-	-	
3	MV019	209	280	258	195	182	237	281	385	219	3	~		
3	MV1019	209	280	258	195/153	182	237	281	385	219	3/4	X	-	
4	MV021	209	280	348	195	164	228	281	463	201	5	~		
4	MV1021	209	280	348	195	164	228	281	463	201	5		~	
5	MV033	209	280	255	195	173	237	281	418	201	6			
5	MV1033	209	280	255	195	173	237	281	418	201	6	✓	-	
6	TK026	209	280	255	195	173	237	281	418	201	6	×		
6	TK1026	209	280	255	195	173/182	237	281	418	201	6/7		-	
7	TV029	209	280	255	195	173	237	281	418	201	6	•		
7	TV1029	209	280	255	195	173	237	281	418	201	6	~	-	
8	TV038	209	280	255	195	173	237	281	418	201	6	^		
8	TV1038	209	280	255	195	173	237	281	418	201	6	~	-	
9	TV040	209	280	255	195	173	237	281	418	201	6	^	•	
9	TV1040	209	280	255	195	173	237	281	418	201	6	~	~	
10	TV048	209	280	255	195	173	237	281	418	201	6	•		
10	TV1048	209	280	255	195	173	237	281	418	201	6	✓	~	
11	TV051	209	280	255	195	173	237	281	418	201	6	~		
11	TV1051	209	280	255	195	173	237	281	418	201	6		-	

402 Table 6. Comparison of microsatellite genotyping data and *pvcrt-o* MS334 and In9*pvcrt* markers results in paired Malaysian isolates.
403 Infections with day 0 versus recurrence differences are highlighted in bold. * Microsatellite-based multi-locus genotype (MLG).





Supplementary File 2. Aligned sequences from the flanking region of *pvcrt-o* in *P. vivax*Sal-1 strain, NIH-1993-S, NIH-1993-R and 5 variants of Malaysian MS334 amplicons.
Positions shown are 200bp upstream from the start of *pvcrt-o* in the Sal-1 strain
(Pv_Sal1_chr01:330,260). Insertion observed in chloroquine resistant progeny NIH-1993-R is
highlighted in red, while region of Malaysian amplicons that contain part of the insertion is
highlighted in yellow. V1 to V5 refers to the MS334 allele variant number observed in Malaysian
population (see Table 3).



414 Supplementary File 3. Aligned sequences of *pvcrt-o* Intron 9 region of *P. vivax* Sal-1 strain, NIH-1993-S, NIH-1993-R and 6 variants of Malaysian isolates. Positions shown are 415 approximately 2.8kbp downstream from the start of *pvcrt-o* in Sal-1 strain (Pv Sal1 chr01:330,260). 416 Deletion observed in chloroquine resistant progeny NIH-1993-R is highlighted in red, while region 417 418 of Malaysian amplicons that contain part of the deletion is highlighted in yellow. V1 to V6 refers 419 to the *In9pvcrt* allele variant number observed in Malaysian population (see **Table 3**).

420